Abstract:BCAT1, a key enzyme in branched‐chain amino acid metabolism, is highly expressed in core‐binding factor‐acute myeloid leukaemia (CBF‐AML) patients compared to other AML subtypes. Mechanistically, RUNX1::ETO and CBFb::MYH11 transactive BCAT1 expression by binding to BCAT1 regulatory elements and also altering its chromatin conformation and promoter–enhancer interaction in a RUNX1‐dependent manner in CBF‐AML. Inhibition of BCAT1 demonstrate significant anti‐leukemic effects on CBF‐AML in vivo and in vitro, which underscores the critical role of BCAT1 in the pathogenesis of CBF‐AML. Summary Effectively targeting transcription factors in therapeutic interventions remains challenging, especially in core‐binding factor‐acute myeloid leukaemia (CBF‐AML) characterized by RUNX1::ETO and CBFβ::MYH11 fusions. However, recent studies have drawn attention towards aberrant amino acid metabolisms as actionable therapeutic targets. Here, by integrating the expression profile and genetic makeup in AML cohort, we found higher BCAT1 expression in CBF‐AML patients compared with other subtypes. Metabolic profiling revealed that high BCAT1 expression led to reprogrammed branch amino acid metabolism in CBF‐AML and was associated with sphingolipid pathway relating to the fitness of leukaemia cells, supported by transcriptomic profiling. Mechanistically, we demonstrated in cell lines and primary patient samples that BCAT1 was directly activated by RUNX1::ETO and CBFβ::MYH11 fusion proteins similarly in a RUNX1‐dependent manner through rewiring chromatin conformation at the BCAT1 gene locus. Furthermore, BCAT1 inhibition resulted in blunted cell cycle, enhanced apoptosis and myeloid differentiation of CBF‐AML cells in vitro, and alleviated leukaemia burden and prolonged survival in vivo. Importantly, pharmacological inhibition of BCAT1 using the specific inhibitor Gabapentin demonstrated therapeutic effects, as evidenced by delayed leukaemia progression and improved survival in vivo. In conclusion, our study uncovers BCAT1 as a genetic vulnerability and a promising targeted therapeutic opportunity for CBF‐AML.

RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core‐binding factor‐acute myeloid leukaemia